Janssen Pharmaceuticals, Inc., part of Johnson & Johnson (J&J), has received approval from the US Food and Drug Administration (FDA) for Invega Trinza (three-month paliperidone palmitate), an atypical antipsychotic indicated to treat schizophrenia. Before starting Invega Trinza, patients must be adequately treated with J&J’s Invega Sustenna (one-month paliperidone palmitate) for at least four months.

Janssen anticipates that Invega Trinza will be commercially available by mid-June.

Source: Johnson & Johnson